Investegate |BiVictriX Therapcts. Announcements | BiVictriX Therapcts.: Director Dealing investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Hemogenyx Pharma Plc Announcements | Hemogenyx Pharma Plc: Appointment of Business Advisor & Board Observer investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
N4 Pharma "at the right place at the right time and not by luck, but by design" says SP Angel (LON:N4P) directorstalkinterviews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from directorstalkinterviews.com Daily Mail and Mail on Sunday newspapers.
Investegate |Hemogenyx Pharma Plc Announcements | Hemogenyx Pharma Plc: Result of Annual General Meeting investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Investegate |Hemogenyx Pharma Plc Announcements | Hemogenyx Pharma Plc: Changes to 2021 AGM Arrangements investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office. The patent was issued as Patent Number US 11,021,536 B2 (https://tinyurl.com/yspjv89w).
This patent covers a method of use of a bi-specific antibody ( CDX ), one of the Company s original and lead product candidates, for conditioning bone marrow/hematopoietic stem cell ( BM/HSC ) transplantation. It also covers a composition of matter (a subset of sequences) of monoclonal antibodies against target proteins existing on the surface of hematopoietic stem cells/hematopoietic progenitors ( HSC/HP ), and/or a number of leukemias such as acute myeloid leukemia ( AML ) as well as a protein that exists on the surface of immune cells (T cells).